Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Circulating microRNAs as stable blood-based markers for cancer detection
- P. S. Mitchell, R. Parkin, +17 authors M. Tewari
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 29 July 2008
It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer. Expand
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
- A. Stephenson, P. Scardino, +17 authors A. Pollack
- Journal of clinical oncology : official journal…
- 20 May 2007
Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence, which should prove valuable for medical decision making for patients with a rising PSA level. Expand
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment. Expand
Incidence of primary urethral carcinoma in the United States.
In the United States, the incidence of urethral carcinoma is relatively higher in men and African Americans, with a histologic profile differing from that previously described. Expand
Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
Major stage category definitional changes are in Tumor-Node-Metastasis classifications of testicular, penile, and prostate cancer which improve patient stratification for prognosis and management. Expand
Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes
- Jonathan L. Wright, E. Kwon, +5 authors E. Mostaghel
- Biology, Medicine
- Cancer Epidemiology, Biomarkers & Prevention
- 31 March 2011
expression and genetic variation in these genes may allow stratification of patients to more aggressive hormonal therapy or earlier incorporation of nonhormonal-based treatment strategies, and may be potential biomarkers for assessing risk of PCSM. Expand
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity.
The results indicate that 3' modification observed in next-generation small RNA sequencing data is a biologically relevant process, and identify enzymatic mechanisms that may lead to new approaches for modulating miRNA activity in vivo. Expand
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.
Evaluation for patients on active surveillance and following definitive therapy for renal neoplasms should include physical examination, renal function, serum studies and imaging and should be tailored according to recurrence risk, comorbidities and monitoring for treatment sequelae. Expand
Castration-resistant prostate cancer: AUA Guideline.
This guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. Expand
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
The 4Kscore showed excellent diagnostic performance in detecting significant PCa and is a useful tool in selecting men who have significant disease and are most likely to benefit from a prostate biopsy from men with no cancer or indolent cancer. Expand